The Global Guillain-Barre Syndrome Market size is expected to reach $852.2 billion by 2030, rising at a market growth of 4.6% CAGR during the forecast period.
North America, particularly the United States and Canada, has a robust healthcare infrastructure with high healthcare spending levels. Thus, the North America segment captured 36.2% revenue share in the market 2022. According to the Government of Canada, since 2014, approximately half of all cases of AFP that have been identified in Canada have been diagnosed with Guillain-Barré syndrome, and approximately twenty percent of those cases have been diagnosed with transverse myelitis.
GBS primarily affects adults, with the highest incidence rates observed in individuals aged 50 and older. As the global population ages, there’s a natural increase in the number of people at risk for GBS, which contributes to the rising prevalence of the condition.
Additionally, according to World Bank data, the World Bank Board of Directors approved US$50 million in new financing for Argentina to improve access to public healthcare services and ensure continued service for 6.5 million residents of the province of Buenos Aires without private health insurance. In conclusion, increasing global healthcare expenditures are driving the market’s growth.
However, the acute phase of GBS often requires hospitalization, intensive care, and specialized medical interventions such as plasma exchange and intravenous immunoglobulin (IVIG) therapy. These treatments can incur substantial healthcare costs, including hospital charges, medication expenses, and physician fees, placing financial strain on patients and healthcare systems. Thus, the high cost of treatment is impeding the market’s growth.
North America, particularly the United States and Canada, has a robust healthcare infrastructure with high healthcare spending levels. Thus, the North America segment captured 36.2% revenue share in the market 2022. According to the Government of Canada, since 2014, approximately half of all cases of AFP that have been identified in Canada have been diagnosed with Guillain-Barré syndrome, and approximately twenty percent of those cases have been diagnosed with transverse myelitis.
GBS primarily affects adults, with the highest incidence rates observed in individuals aged 50 and older. As the global population ages, there’s a natural increase in the number of people at risk for GBS, which contributes to the rising prevalence of the condition.
Additionally, according to World Bank data, the World Bank Board of Directors approved US$50 million in new financing for Argentina to improve access to public healthcare services and ensure continued service for 6.5 million residents of the province of Buenos Aires without private health insurance. In conclusion, increasing global healthcare expenditures are driving the market’s growth.
However, the acute phase of GBS often requires hospitalization, intensive care, and specialized medical interventions such as plasma exchange and intravenous immunoglobulin (IVIG) therapy. These treatments can incur substantial healthcare costs, including hospital charges, medication expenses, and physician fees, placing financial strain on patients and healthcare systems. Thus, the high cost of treatment is impeding the market’s growth.
By Therapeutics Analysis
Based on therapeutics, the market is bifurcated into intravenous immunoglobulin, plasma exchange, and others. In 2022, the intravenous immunoglobulin segment garnered 50.9% revenue share in the market. Intravenous immunoglobulin exerts its therapeutic effects through multiple mechanisms, including modulating immune responses.By Route Of Administration Analysis
On the basis of the route of administration, the market is segmented into parenteral and oral. In 2022, the oral segment attained a noteworthy revenue share in the market. Oral medications are increasingly utilized for early intervention in GBS cases with mild symptoms or as maintenance therapy following the acute phase of the disease.
By Distribution Channel Analysis
Based on distribution channel, the market is categorized into retail pharmacies, hospital pharmacies, and others. In 2022, the hospital pharmacies segment registered 48.8% revenue share in the market. GBS management typically involves a multidisciplinary team of healthcare professionals, including neurologists, intensivists, physiotherapists, and pharmacists, working together to provide comprehensive patient care.By Regional Analysis
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region generated 28.2% revenue share in the market. The diagnostic rate of neurological illnesses, including GBS, has improved in the Asia-Pacific region due to increased public and healthcare professional knowledge.List of Key Companies Profiled
- F.Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- PTC, Inc.
- AstraZeneca PLC
- Novartis AG
- Novo Nordisk A/S
- Takeda Pharmaceutical Company Limited
- Bayer AG
- Merck & Co., Inc.
- Bristol Myers Squibb Company
Market Report Segmentation
By Therapeutics- Intravenous Immunoglobulin
- Plasma Exchange
- Others
- Parenteral
- Oral
- Hospital Pharmacies
- Retail Pharmacies
- Others
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Global Guillain-Barre Syndrome Market by Therapeutics
Chapter 5. Global Guillain-Barre Syndrome Market by Route Of Administration
Chapter 6. Global Guillain-Barre Syndrome Market by Distribution Channel
Chapter 7. Global Guillain-Barre Syndrome Market by Region
Chapter 8. Company Profiles
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- PTC, Inc.
- AstraZeneca PLC
- Novartis AG
- Novo Nordisk A/S
- Takeda Pharmaceutical Company Limited
- Bayer AG
- Merck & Co., Inc.
- Bristol Myers Squibb Company
Methodology
LOADING...
